Fig. 6From: Cost-effectiveness analysis for midostaurin versus standard of care in acute myeloid leukemia in the United KingdomAdditional scenario analysis results (incremental cost-effectiveness ratio per quality-adjusted life year). OS overall survival, EFS event-free survival, CCR conventional chemotherapy regimen, AZA azacitidineBack to article page